SEARCH

SEARCH BY CITATION

References

  • Ardeshna, K.M., Smith, P., Norton, A., Hancock, B.W., Hoskin, P.J., MacLennan, K.A., Marcus, R.E., Jelliffe, A., Vaughan, G., Hudson, G.V. & Linch, D.C. (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet, 362, 516522.
  • Bachy, E., Houot, R., Morschhauser, F., Sonet, A., Brice, P., Belhadj, K., Cartron, G., Audhuy, B., Ferme, C., Feugier, P., Sebban, C., Delwail, V., Maisonneuve, H., Le Gouill, S., Lefort, S., Brousse, N., Foussard, C., Salles, G. & Groupe d'Etude des Lymphomes de, l.A. (2013) Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica, 98, 11071114.
  • Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haioun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah, I. & Solal-Celigny, P. (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 15, 11101117.
  • Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
  • Coiffier, B., Osmanov, E.A., Hong, X., Scheliga, A., Mayer, J., Offner, F., Rule, S., Teixeira, A., Walewski, J., de Vos, S., Crump, M., Shpilberg, O., Esseltine, D.L., Zhu, E., Enny, C., Theocharous, P., van de Velde, H., Elsayed, Y.A., Zinzani, P.L. & Investigators, L.Y.M.s. (2011) Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology, 12, 773784.
  • Coiffier, B., Li, W., Henitz, E.D., Karkera, J.D., Favis, R., Gaffney, D., Shapiro, A., Theocharous, P., Elsayed, Y.A., van de Velde, H., Schaffer, M.E., Osmanov, E.A., Hong, X., Scheliga, A., Mayer, J., Offner, F., Rule, S., Teixeira, A., Romejko-Jarosinska, J., de Vos, S., Crump, M., Shpilberg, O., Zinzani, P.L., Cakana, A., Esseltine, D.L., Mulligan, G. & Ricci, D. (2013) Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab. Clinical Cancer Research, 19, 25512561.
  • Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Stamatoullas, A., Milpied, N., Boue, F., Taillan, B., Lederlin, P., Najman, A., Thieblemont, C., Montestruc, F., Mathieu-Boue, A., Benzohra, A. & Solal-Celigny, P. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood, 97, 101106.
  • Di Bella, N., Taetle, R., Kolibaba, K., Boyd, T., Raju, R., Barrera, D., Cochran E.W. Jr, Dien, P.Y., Lyons, R., Schlegel, P.J., Vukelja, S.J., Boston, J., Boehm, K.A., Wang, Y. & Asmar, L. (2010) Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood, 115, 475480.
  • Federico, M., Luminari, S., Dondi, A., Tucci, A., Vitolo, U., Rigacci, L., Di Raimondo, F., Carella, A.M., Pulsoni, A., Merli, F., Arcaini, L., Angrilli, F., Stelitano, C., Gaidano, G., Dell'olio, M., Marcheselli, L., Franco, V., Galimberti, S., Sacchi, S. & Brugiatelli, M. (2013) R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology, 31, 15061513.
  • Fowler, N., Kahl, B.S., Lee, P., Matous, J.V., Cashen, A.F., Jacobs, S.A., Letzer, J., Amin, B., Williams, M.E., Smith, S., Saleh, A., Rosen, P., Shi, H., Parasuraman, S. & Cheson, B.D. (2011) Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. Journal of Clinical Oncology, 29, 33893395.
  • Friedberg, J.W., Vose, J.M., Kelly, J.L., Young, F., Bernstein, S.H., Peterson, D., Rich, L., Blumel, S., Proia, N.K., Liesveld, J., Fisher, R.I., Armitage, J.O., Grant, S. & Leonard, J.P. (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood, 117, 28072812.
  • Ghielmini, M., Schmitz, S.F., Cogliatti, S.B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M.F., Betticher, D.C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsovics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D. & Cerny, T. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood, 103, 44164423.
  • Hainsworth, J.D., Litchy, S., Burris, H.A. 3rd, Scullin, D.C. Jr, Corso, S.W., Yardley, D.A., Morrissey, L. & Greco, F.A. (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. Journal of Clinical Oncology, 20, 42614267.
  • Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K.H., Neubauer, A., Dolken, G., Naumann, R., Knauf, W., Freund, M., Rohrberg, R., Hoffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M. & von Grunhagen, U. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology, 25, 19861992.
  • Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 37253732.
  • Kahl, B.S., Williams, M.E., Hong, F., Gascoyne, R. & Horning, S.J. (2007) Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT). Blood, 110, 3420a.
  • Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith, P. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, 14171423.
  • Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J.V., Dmoszynska, A., Raposo, J.C., Offner, F.C., Gomez-Codina, J., Belch, A., Cunningham, D., Wassner-Fritsch, E. & Stein, G. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Journal of Clinical Oncology, 26, 45794586.
  • Martinelli, G., Schmitz, S.F., Utiger, U., Cerny, T., Hess, U., Bassi, S., Okkinga, E., Stupp, R., Stahel, R., Heizmann, M., Vorobiof, D., Lohri, A., Dietrich, P.Y., Zucca, E. & Ghielmini, M. (2010) Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. Journal of Clinical Oncology, 28, 44804484.
  • O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. & Zelenetz, A.D. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676684.
  • O'Connor, O.A., Portlock, C., Moskowitz, C., Hamlin, P., Straus, D., Gerecitano, J., Gonen, M., Dumitrescu, O., Sarasohn, D., Butos, J., Neylon, E., Mac-Gregor Cortelli, B., Blumel, S., Evens, A.M., Zelenetz, A.D., Wright, J., Cooper, B., Winter, J. & Vose, J. (2010) Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clinical Cancer Research, 16, 719726.
  • Petrucci, M.T., Giraldo, P., Corradini, P., Teixeira, A., Dimopoulos, M.A., Blau, I.W., Drach, J., Angermund, R., Allietta, N., Broer, E., Mitchell, V. & Bladé, J. (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. British Journal of Haematology, 160, 649659.
  • Ribrag, V., Tilly, H., Casasnovas, O., Bosly, A., Bouabdallah, R., Delarue, R., Boue, F., Bron, D., Feugier, P., Haioun, C., Offner, F. & Coiffier, B. (2013) Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). European Journal of Cancer, 49, 904910.
  • Rummel, M.J., Niederle, N., Maschmeyer, G., Banat, G.A., von Grunhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., Kaiser, U., Weidmann, E., Durk, H., Ballo, H., Stauch, M., Roller, F., Barth, J., Hoelzer, D., Hinke, A., Brugger, W. & Study group indolent, L. (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 381, 12031210.
  • Salles, G., Mounier, N., de Guibert, S., Morschhauser, F., Doyen, C., Rossi, J.F., Haioun, C., Brice, P., Mahe, B., Bouabdallah, R., Audhuy, B., Ferme, C., Dartigeas, C., Feugier, P., Sebban, C., Xerri, L. & Foussard, C. (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood, 112, 48244831.
  • Salles, G., Seymour, J.F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J.V., Brice, P., Caballero, D., Haioun, C., Pedersen, L.M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., Intragumtornchai, T., Ferme, C., da Silva, M.G., Sebban, C., Lister, A., Estell, J.A., Milone, G., Sonet, A., Mendila, M., Coiffier, B. & Tilly, H. (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 377, 4251.
  • Sehn, L.H., MacDonald, D., Rubin, S., Cantin, G., Rubinger, M., Lemieux, B., Basi, S., Imrie, K., Gascoyne, R.D., Sussman, J., Chen, B.E., Djurfeldt, M., Shepherd, L., Couban, S. & Crump, M. (2011) Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 29, 33963401.
  • Solal-Celigny, P., Lepage, E., Brousse, N., Tendler, C.L., Brice, P., Haioun, C., Gabarre, J., Pignon, B., Tertian, G., Bouabdallah, R., Rossi, J.F., Doyen, C. & Coiffier, B. (1998) Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. Journal of Clinical Oncology, 16, 23322338.
  • de Vos, S., Goy, A., Dakhil, S.R., Saleh, M.N., McLaughlin, P., Belt, R., Flowers, C.R., Knapp, M., Hart, L., Patel-Donnelly, D., Glenn, M., Gregory, S.A., Holladay, C., Zhang, T. & Boral, A.L. (2009) Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. Journal of Clinical Oncology, 27, 50235030.